255 related articles for article (PubMed ID: 7739522)
1. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias.
Tanaka T; Mitani K; Kurokawa M; Ogawa S; Tanaka K; Nishida J; Yazaki Y; Shibata Y; Hirai H
Mol Cell Biol; 1995 May; 15(5):2383-92. PubMed ID: 7739522
[TBL] [Abstract][Full Text] [Related]
2. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence.
Kurokawa M; Ogawa S; Tanaka T; Mitani K; Yazaki Y; Witte ON; Hirai H
Oncogene; 1995 Sep; 11(5):833-40. PubMed ID: 7675444
[TBL] [Abstract][Full Text] [Related]
3. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.
Mitani K; Ogawa S; Tanaka T; Miyoshi H; Kurokawa M; Mano H; Yazaki Y; Ohki M; Hirai H
EMBO J; 1994 Feb; 13(3):504-10. PubMed ID: 8313895
[TBL] [Abstract][Full Text] [Related]
4. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
5. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
Kurokawa M; Mitani K; Imai Y; Ogawa S; Yazaki Y; Hirai H
Blood; 1998 Dec; 92(11):4003-12. PubMed ID: 9834202
[TBL] [Abstract][Full Text] [Related]
6. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of blastic crisis in chronic myelocytic leukemia.
Mitani K
Leukemia; 1997 Apr; 11 Suppl 3():503-5. PubMed ID: 9209439
[TBL] [Abstract][Full Text] [Related]
8. The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP.
Izutsu K; Kurokawa M; Imai Y; Ichikawa M; Asai T; Maki K; Mitani K; Hirai H
Oncogene; 2002 Apr; 21(17):2695-703. PubMed ID: 11965542
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of leukemogenesis by AML1/EVI-1.
Mitani K
Oncogene; 2004 May; 23(24):4263-9. PubMed ID: 15156182
[TBL] [Abstract][Full Text] [Related]
10. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
11. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties.
Zent CS; Mathieu C; Claxton DF; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1044-8. PubMed ID: 8577711
[TBL] [Abstract][Full Text] [Related]
12. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
Zent C; Rowley JD; Nucifora G
Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
[TBL] [Abstract][Full Text] [Related]
13. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations.
Nucifora G; Begy CR; Kobayashi H; Roulston D; Claxton D; Pedersen-Bjergaard J; Parganas E; Ihle JN; Rowley JD
Proc Natl Acad Sci U S A; 1994 Apr; 91(9):4004-8. PubMed ID: 8171026
[TBL] [Abstract][Full Text] [Related]
14. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
[TBL] [Abstract][Full Text] [Related]
15. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
Fears S; Mathieu C; Zeleznik-Le N; Huang S; Rowley JD; Nucifora G
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1642-7. PubMed ID: 8643684
[TBL] [Abstract][Full Text] [Related]
16. [Study of genes involved in chronic myeloid leukemia with t (3; 21) (q26; q22) in blastic crisis].
Liu XP; Zhang MR; Dai Y; Zhang L; Li R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):310-3. PubMed ID: 16875579
[TBL] [Abstract][Full Text] [Related]
17. Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain.
Tanaka T; Nishida J; Mitani K; Ogawa S; Yazaki Y; Hirai H
J Biol Chem; 1994 Sep; 269(39):24020-6. PubMed ID: 7929053
[TBL] [Abstract][Full Text] [Related]
18. [Leukemogenesis by the AML1/EVI-1 chimeric protein].
Mitani K; Hirai H
Tanpakushitsu Kakusan Koso; 2000 Jan; 45(1):33-9. PubMed ID: 10643333
[No Abstract] [Full Text] [Related]
19. Leukemogenesis by the chromosomal translocations.
Mitani K
Leukemia; 1997 Apr; 11 Suppl 3():294-6. PubMed ID: 9209370
[TBL] [Abstract][Full Text] [Related]
20. DNA-binding domain of AML1, expressed in t(8;21) and t(3;21) myeloid leukemias, inhibits PEBP2/CBF DNA-binding but is not sufficient to transform 32D cl3 myeloid cells.
Britos-Bray M; Sacchi N; Friedman AD
Leukemia; 1996 Jun; 10(6):984-90. PubMed ID: 8667656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
